ZIRCONIUM-RADIOLABELED, CYSTEINE ENGINEERED ANTIBODY CONJUGATES
    2.
    发明申请
    ZIRCONIUM-RADIOLABELED, CYSTEINE ENGINEERED ANTIBODY CONJUGATES 审中-公开
    青霉素 - 放射性标记物,CYSTEINE工程抗体结合蛋白

    公开(公告)号:US20150017094A1

    公开(公告)日:2015-01-15

    申请号:US14300630

    申请日:2014-06-10

    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab) are conjugated with one or more zirconium complex (Z) labels through a linker (L) to form cysteine engineered zirconium-labeled antibody conjugates having Formula I: Ab-(L-Z)p  I where p is 1 to 4. Imaging methods and diagnostic uses for zirconium-radiolabeled, cysteine engineered antibody conjugate compositions are disclosed.

    Abstract translation: 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段(ThioFab)。 提供了设计,制备,筛选和选择半胱氨酸改造的抗体的方法。 半胱氨酸改造的抗体(Ab)通过接头(L)与一个或多个锆络合物(Z)标记物缀合以形成具有式I:Ab-(LZ)p I的半胱氨酸改造的锆标记的抗体缀合物,其中p为1至4 公开了用于放射性标记的半胱氨酸改造的抗体缀合物组合物的成像方法和诊断用途。

Patent Agency Ranking